KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Other Operating Expenses (2016 - 2025)

Biogen has reported Other Operating Expenses over the past 17 years, most recently at -$34.1 million for Q3 2025.

  • Quarterly results put Other Operating Expenses at -$34.1 million for Q3 2025, down 130.41% from a year ago — trailing twelve months through Dec 2025 was -$102.5 million (down 415.08% YoY), and the annual figure for FY2024 was $88.6 million, changed.
  • Other Operating Expenses for Q3 2025 was -$34.1 million at Biogen, up from -$68.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for BIIB hit a ceiling of $964.1 million in Q4 2021 and a floor of -$502.9 million in Q3 2021.
  • Median Other Operating Expenses over the past 5 years was -$13.7 million (2022), compared with a mean of $6.8 million.
  • Biggest five-year swings in Other Operating Expenses: tumbled 1834.14% in 2021 and later soared 3204.76% in 2023.
  • Biogen's Other Operating Expenses stood at $964.1 million in 2021, then plummeted by 101.42% to -$13.7 million in 2022, then skyrocketed by 606.57% to $69.4 million in 2023, then tumbled by 121.33% to -$14.8 million in 2024, then tumbled by 130.41% to -$34.1 million in 2025.
  • The last three reported values for Other Operating Expenses were -$34.1 million (Q3 2025), -$68.4 million (Q1 2025), and -$14.8 million (Q3 2024) per Business Quant data.